ERC Synergy Grant for Immunotherapy of Liver Metastases
10/26/2023Four distinguished immunologists have been awarded one of the most generously funded research grants from the EU: the ERC Synergy Grant. They aim to explore new avenues for immunotherapy of liver metastases.
A significant proportion of cancer patients do not succumb to the initial tumor but rather to the resulting metastases. The growth of these secondary cancer sites is often challenging to curb with conventional therapies. Colorectal tumors, as well as many other types of tumors, frequently metastasize to the liver. Therefore, new treatment approaches are urgently needed and would benefit many patients.
"We aim to combine our expertise and techniques to investigate the local immune system of the liver: how do various cell types communicate and function in the healthy organ, and how do they change in the diseased tissue. The goal is to develop new strategies to harness the potential of innate immune cells in the liver for the treatment of metastatic diseases," summarizes immunologist Georg Gasteiger of the Max Planck Research Group for Systems Immunology at Julius-Maximilians-Universität (JMU) Würzburg and the team's principal investigator.
An approach that the European Research Council sees great potential in: Synergy Grants exclusively support highly innovative, potentially groundbreaking research approaches that could set new global standards. The team convinced an international panel of experts with their scientific proposals and its project "TREATLIVMETS: Treating Liver Metastasis" has been awarded the maximum amount of 10 million EUR for a 6-year period.
Newly Developed Molecules as a Therapeutic Approach
The four scientists conduct research in Italy, France, and Germany. They are each regarded as leaders in their respective fields:
Valeria Fumagalli specializes in liver immunology and works with tissue samples from cancer patients at San Raffaele Hospital in Milan.
Florent Ginhoux from the Gustave Roussy Cancer Campus in Paris is an expert in the biology of myeloid cells and their function in healthy versus diseased tissues.
Georg Gasteiger's work focuses on lymphocytes of the innate immune system, including "Natural Killer" or NK cells, and their development and function in various body tissues.
Eric Vivier from Centre d'Immunologie de Marseille-Luminy has already developed several molecules that can activate these cells to fight against tumors and has successfully brought them into clinical trials with patients.
Drawing from these experiences, the team aims to develop new approaches to immunotherapy.
The scientists will examine tissue and tumor samples from patients using state-of-the-art, high-resolution single-cell and spatial transcriptomics. Their aim is to elucidate the communication and interactions among immune cells themselves and with various liver cells, and how these change during the disease. The goal is to identify key molecules and checkpoints in complex cellular interaction networks, and to leverage them for the restoration of immune control in metastatic lesions. The researchers plan to develop new molecules that can regulate cellular interactions. These molecules will then be tested in experimental mouse models and on patient tissue samples to explore new therapeutic approaches for this devastating disease. "We hope that such approaches for modulating the local immune system can be applied to or further developed for other diseases and tissues in the future," says Georg Gasteiger.
ERC Synergy Grants for Groundbreaking Research
The European Research Council (ERC) is the primary European funding organization for pioneering research. It supports creative researchers from all disciplines, nationalities, and age groups who conduct projects across Europe. Established by the European Union in 2007, it is part of the "Horizon Europe" program. Its total budget for the period from 2021 to 2027 amounts to over 16 billion EUR.
Synergy Grants are awarded for projects that bring together the expertise of various experts, thereby enabling significant advances at the frontiers of knowledge. These advances may build on promising new research findings or methods and techniques, including unconventional approaches and investigations at the intersection of established disciplines. The transformative research supported by Synergy Grants should have the potential to set new global standards. Synergy Grants can be awarded for a maximum amount of 10 million EUR over a period of 6 years.
About the Max Planck Research Group
The Max Planck Research Group for Systems Immunology is a collaborative effort between the Julius-Maximilians-Universität (JMU) Würzburg and the Max Planck Society (MPG) aimed at promoting excellent immunological research. Around 50 researchers from more than 20 countries are working together to understand the basis of a successful immune response against infectious agents, chronic inflammatory diseases, and tumors. Their ultimate goal is to develop new concepts and strategies for vaccines and immunotherapies.
To achieve this, the group is investigating the development and function of the immune system holistically at multiple levels. They are conducting high-resolution analyses of single molecules and cells, examining complex cellular networks within organs, and exploring systemic interactions in the body and with the environment. These research goals align well with the internationally visible research on infectious diseases and immunotherapies at the Würzburg Life Science Campus.
Weblink
Research Alliance Immunomedicine
The University of Würzburg is part of the research alliance immunomedicine (Forschungsallianz Immunmedizin). The aim of this alliance is the development of new diagnostic tools and therapies for major common diseases such as infections, cancer and autoimmune diseases. The alliance networks complementary strategies of the University sites Erlangen-Nürnberg, Regensburg and Würzburg and develops synergistic key areas to strengthen immunomedicine at the highest level in northern and eastern Bavaria.
Additional images
